Drug Safety & Risk Management

Online Registration is open!

Have a question about this event?
Customer Service representatives are available to help from 8 AM - 6 PM EST
Call 888-670-8200

Need Technical Assistance With this Website?
Send an email to IIR's Web Department

Advanced Search

Home»Events»Drug Safety & Risk M...Event Overview

Drug Safety & Risk Management

May 21 - 23, 2008 | National Harbor, Oxon Hill, MD

Event Overview

Guaranteed 1 to 1 ratio of pharma participants to service provider in attendance!

Keynote Session:

The Future of Risk Management: Active Safety Surveillance Programs to Mitigate Risk

Mark McClellan, MPA, MD, PHD,
Director of the Engelberg Center for Healthcare Reform,
BROOKINGS INSTITUTION,
Administrator, CENTERS FOR MEDICARE & MEDICAID SERVICES (2004-2006) and Commissioner, FDA (2002-2004)

Conference Chair:

Songlin Xue, MD, PhD,
Vice President and Global Head Clinical Epidemiology,
NOVARTIS PHARMACEUTICALS

Keynote & Featured Sessions:

Come to grips with how to manage the public’s new access to information & how this new knowledge impacts your drug’s perception
The Public Perception of the Pharmaceutical Industry and Drug Safety: Implications on the Culture of Safety

Axel K. Olsen, PhD,
President,
THE PHARMACEUTICAL SAFETY INSTITUTE

Take away your best way forward through the maze of increased regulatory scrutiny
Comparing Post-Approval Research (PAR) Required by FDA, EMEA and MHLW

Christopher-Paul Milne, DV, MPH, JD,
Associate Director,
TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

Optimizing EHRs for improved Drug Safety Today!
Increasing Pharmaceutical Safety Using Electronic Health Records

Michael A. Ibara,
Head of Pharmacovigilance Information Management,
PFIZER

Register Now and Be the First to Apply to Our Exclusive Invite-Only, Executive Task Force

For the first time ever, 50 key pharma risk management leaders will convene for an Exclusive Executive Task Force. This unique pharma working group will discuss the most urgent issues and potential solutions/actions to take in managing drug safety risk under the microscope of post-approval regulation.

These industry leaders…

Carmen Bozic, BIOGEN IDEC
Paul Coplan, WYETH RESEARCH
John Ferguson, NOVARTIS
David Haddox, PURDUE PHARMACEUTICALS
Mary Frances Schubert, MERCK

…will hash out the real issues with moderator Christopher Milne.

The Task Force suggested action points will be delivered at the main conference in a discussion panel led by Peggy Schrammel, of Pharmanet.

This Exclusive Full Day Task Force is limited to pharmaceutical company participants ONLY

In Collaboration With: